Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Resolution Pharmaceuticals Inc.

Latest From Resolution Pharmaceuticals Inc.

Genfit Dives Into Uncertain Late-stage NASH Trial

Gastrointestinal Orthopedics

AbbVie In Hot Seat Over HCV Drugs' Serious Liver Injury Risk

The US FDA's alert about liver failure and death in patients taking AbbVie Inc.'s hepatitis C fixed-dose combination therapies Viekira Pak and Technivie is a significant setback for a company that already is a distant second in the market behind Gilead Sciences Inc., and the agency's move clears the way for HCV newcomer Merck & Co. Inc.

FDA: AZ/Ardea Gout Drug Modest Efficacy, Safety Concerns

An experimental gout drug from AstraZeneca plc unit Ardea Biosciences Inc., known as lesinurad, demonstrated only modest efficacy in clinical trials and has some concerning adverse cardiovascular (CV) and renal-related effects, FDA drug reviewers said on Oct. 21.

Metabolic Disorders Cardiovascular

Amgen: Apotex Lost Bet; Biosimilar Should Be Blocked

With the FDA set to make a decision any day on whether it will approve Apotex Corp.'s pegfilgrastim biosimilar, Amgen Inc. is seeking to block the product from entering the US market for at least six months after the medicine gains the agency's blessing.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals